Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
US-9873740-B2 · Jan 23, 2018 · US
Regulatory T cell activator and use thereof
US11059888B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11059888-B2 |
| Application number | US-201716095024-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 19, 2017 |
| Priority date | Apr 20, 2016 |
| Publication date | Jul 13, 2021 |
| Grant date | Jul 13, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A regulatory T cell activator including a substance that inhibits the binding between DNAX accessory molecule-1 (DNAM-1) and CD155.
First claim
Opening claim text (preview).
The invention claimed is: 1. An anti-human DNAM-1 monoclonal antibody or a fragment thereof, comprising a heavy-chain variable region having the amino acid sequence of SEQ ID NO: 7 and a light-chain variable region having the amino acid sequence of SEQ ID NO: 8. 2. The anti-human DNAM-1 monoclonal antibody or a fragment thereof according to claim 1 , the antibody or a fragment thereof being a humanized antibody or a fragment of a humanized type antibody.
Assignees
Inventors
Classifications
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Cells modified by introduction of foreign genetic material · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Complementarity determining region [CDR] · CPC title
from primates, e.g. man · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11059888B2 cover?
- A regulatory T cell activator including a substance that inhibits the binding between DNAX accessory molecule-1 (DNAM-1) and CD155.
- Who is the assignee on this patent?
- Univ Tsukuba
- What technology area does this patent fall under?
- Primary CPC classification A61K39/395. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).